(Q40905525)

24 September 2017

title

Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials (English)

1 reference

24 September 2017

main subject

metastatic breast cancer

1 reference

1 reference

4

Case LD

1 reference

24 September 2017

Kuss JT

1

1 reference

24 September 2017

Muss HB

series ordinal

2

1 reference

24 September 2017

Hoen H

series ordinal

3

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 February 1997

1 reference

Breast Cancer Research and Treatment

24 September 2017

published in

1 reference

24 September 2017

volume

42

1 reference

24 September 2017

issue

3

1 reference

24 September 2017

page(s)

265-274

1 reference

On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005758127114

Endocrine therapy for advanced breast cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005758127114

Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005758127114

Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005758127114

7 January 2021

Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005758127114

7 January 2021

Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005758127114

7 January 2021

Censoring distributions as a measure of follow-up in survival analysis

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005758127114

7 January 2021

Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005758127114

7 January 2021

Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005758127114

7 January 2021

Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005758127114

7 January 2021

A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Aust

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005758127114

7 January 2021

Identifiers

DOI

10.1023/A:1005758127114

1 reference

Dimensions Publication ID

24 September 2017

1011814943

0 references

1 reference